November 18, 2016 (Shareholders Foundation) - An investigation on behalf of investors of Intersect ENT Inc (NASDAQ:XENT) shares over potential securities laws violations by Intersect ENT and certain of its directors and officers in connection certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Intersect ENT Inc (NASDAQ:XENT) concerning whether a series of statements regarding Intersect ENT Incs business, its prospects and its operations were materially false and misleading at the time they were made.

Commercial stage drug-device company Intersect ENT Inc conducted its initial public offering in July 2014. Shares of Intersect ENT Inc (NASDAQ:XENT) grew from $12.30 per share in August 2014 to as high as $32.44 per share in July 2015.

Menlo Pakr, CA based Intersect ENT Inc reported that its annual Total Revenue rose from 38.59 per million in 2014 to $61.59 million in 2015 while its Net Loss increased from $18.36 million in 2014 to $26.63 million in 2015.

On November 2, 2016, Intersect ENT Inc reported its third quarter 2016 results and updated its 2016 outlook.

Shares of Intersect ENT Inc (NASDAQ:XENT) declined on November 2, 2016 to as low as $7.65 per share.